Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Urology ; 75(4): 873-7, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20022086

ABSTRACT

OBJECTIVES: To examine the effects of combined use of trospium chloride and melatonin on in vitro contractility of rat urinary bladder. METHODS: Isolated bladder strips from 20 male Wistar rats were examined in an organ bath. Contractions were evoked by acetylcholine (ACh). Initially, effective concentrations of trospium and melatonin to inhibit the contractions were determined. We subsequently tested the effects of combined use of melatonin and trospium on agonist-induced contractions. RESULTS: Exposure of bladder strips to 10 microM ACh significantly increased the contractions. After cumulative administration of increasing concentrations of trospium (1, 3, and 5 microM), agonist-induced contractions decreased significantly (P <.05). Similarly, the mean peak amplitude of contractions evoked by ACh was significantly inhibited by melatonin in a concentration-dependent manner (100, 200, and 300 microM) (P <.05). Further evaluation of the effects of combined use of trospium and melatonin on ACh-induced contractions of bladder strips revealed that one-tenth of initially applied dose of trospium (500 nM) in addition to the lowest inhibitory dose of melatonin (100 microM) significantly lowered both the peak amplitude and area under the contractility curve of contractions (P <.05). CONCLUSIONS: Our results showed that combined use of low dose trospium and melatonin had strong in vitro inhibitory capability on agonist-induced contractions of rat bladder strips. The present findings may offer an insight into lowering the dose of an antimuscarinic by combining it with an antioxidant and endogenous hormone, melatonin.


Subject(s)
Melatonin/administration & dosage , Muscarinic Antagonists/administration & dosage , Muscle Contraction/drug effects , Nortropanes/administration & dosage , Urinary Bladder/drug effects , Urinary Bladder/physiology , Animals , Benzilates , Drug Combinations , Drug Synergism , In Vitro Techniques , Male , Rats , Rats, Wistar
2.
Urol Int ; 75(1): 75-9, 2005.
Article in English | MEDLINE | ID: mdl-16037713

ABSTRACT

PURPOSE: To evaluate erectile dysfunction, penile color Doppler ultrasound is currently considered the best method. But intracavernous injection is invasive and has adverse effects, such as prolonged erection and risk of priapism. In our study we want to evaluate whether vardenafil can be used instead of papaverine in penile Doppler ultrasonography. MATERIALS AND METHODS: A total of 24 patients with erectile dysfunction underwent color Doppler ultrasound before and after intracavernous injection of 60 mg papaverine with genital and audiovisual sexual stimulation. Peak flow and end diastolic velocity were measured in the recorded waveforms obtained 0, 1, 5, 10 and 20 min after injection. The patients also underwent color Doppler ultrasound after a 10-mg oral dose of vardenafil with genital and audiovisual sexual stimulation and at least 5 days after the prior examination. The same parameters were measured at 30, 45, 60, 75 and 90 min after the drug administration. We compared the results with the values obtained after papaverine injection. RESULTS: After oral vardenafil mean peak flow velocity significantly increased starting at 30 min and achieving a maximum value at 60 min. There were no significant differences in the 2 methods in mean peak velocity 1, 5, 10 and 20 min after papaverine injection, and 30, 45, 60, 75 and 90 min after oral vardenafil administration. Although papaverine injection is the gold standard for penile color Doppler ultrasound, it has severe adverse effects such as prolonged erection which we observed in 3 patients (12.5%) and required pharmacological detumescence. After vardenafil no severe adverse effects were observed. CONCLUSIONS: Vardenafil administration achieved increased peak flow velocity comparable to that after intracavernous papaverine injection. With no prolonged erection vardenafil is a safer alternative compared to more invasive intracavernous injection and is also an alternative for patients who fear injections.


Subject(s)
Erectile Dysfunction/drug therapy , Imidazoles/therapeutic use , Papaverine/therapeutic use , Penile Erection/drug effects , Phosphodiesterase Inhibitors/therapeutic use , Piperazines/therapeutic use , Ultrasonography, Doppler, Color , Adult , Arteries/diagnostic imaging , Arteries/drug effects , Arteries/physiopathology , Blood Flow Velocity/drug effects , Drug Administration Routes , Erectile Dysfunction/diagnostic imaging , Erectile Dysfunction/physiopathology , Follow-Up Studies , Humans , Imidazoles/administration & dosage , Male , Middle Aged , Papaverine/administration & dosage , Penile Erection/physiology , Penis/blood supply , Penis/diagnostic imaging , Phosphodiesterase Inhibitors/administration & dosage , Piperazines/administration & dosage , Sulfones/administration & dosage , Sulfones/therapeutic use , Triazines/administration & dosage , Triazines/therapeutic use , Vardenafil Dihydrochloride
SELECTION OF CITATIONS
SEARCH DETAIL
...